Year
DEALS // DEV.
Country
Therapeutic Area
Study Phase
Deal Type
Product Type
Dosage Form
Lead Product
Target
Lead Product(s) : Worm-derived Drug
Therapeutic Area : Immunology
Study Phase : Discovery Platform
Sponsor : BOLD Capital Partners
Deal Size : $16.0 million
Deal Type : Series A Financing
Holoclara Announces $16 Million Series A for Worm-Derived Therapies for Autoimmune Disease
Details : The capital will be used to support clinical development of first-in-class, worm-derived medicines for allergies and autoimmune disorders and advancement of discovery engine.
Brand Name : Undisclosed
Molecule Type : Large molecule
Upfront Cash : Undisclosed
June 27, 2024
Lead Product(s) : Worm-derived Drug
Therapeutic Area : Immunology
Highest Development Status : Discovery Platform
Sponsor : BOLD Capital Partners
Deal Size : $16.0 million
Deal Type : Series A Financing
LOOKING FOR A SUPPLIER?